1378391-43-5

Basic information

• Product Name: Velpatasvir intermediate
• Synonyms: VP N-3;(2R,4R)-1-tert-butyl 2-(2-(9-((2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-5-methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate;Velpatasvir intermediate N-4;1-tert-Butyl 2-[2-[9-[[[(2S,5S)-1-[(S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]carbonyl]oxy]-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl]-2-oxoethyl] (2S,4S)-4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate;Velpatasvir N-3
• CAS NO: 1378391-43-5
• Molecular Formula: C₄₄H₅₅N₃O₁₃
• Molecular Weight: 833.9198
• EINECS: -0
• Mol File: 1378391-43-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Velpatasvir intermediate(CAS DataBase Reference)
• NIST Chemistry Reference: Velpatasvir intermediate(1378391-43-5)
• EPA Substance Registry System: Velpatasvir intermediate(1378391-43-5)

Safety Data

• Hazardous Substances Data: 1378391-43-5(Hazardous Substances Data)

Usage

General Description

Velpatasvir intermediate is a chemical compound used in the synthesis of Velpatasvir, an antiviral medication primarily used for treating hepatitis C. This intermediate compound plays a crucial role in the formation of the final pharmaceutical product. Velpatasvir intermediate can exist in various forms or stages, each of which contributes to the efficacy and potency of the final Velpatasvir drug. Due to its significant role in the production of this important medication, stringent quality control and production processes are typically maintained while handling and synthesizing Velpatasvir intermediate.

Upstream product

• 1378388-16-9 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(methoxymethyl)-pyrrolidine-2-carboxylic acid 
• 1438383-89-1 9-bromo-3-(2-bromoacetyl)-10,11-dihydro-5H-benzo[d]naphtho[2,3-b]pyran-8(9H)-one 
• 1378388-20-5 3-chloro-10,11-dihydro-5H-benzo[d]naphtho[2,3-b]pyran-8(9H)-one 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 66192-24-3 2-bromo-5-chlorobenzyl bromide 
• 22009-38-7 7-hydroxy-1-tetralone 
• 1378388-37-4 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(methoxymethyl)-pyrrolidine-2-carboxylic acid methyl ester 
• 1378393-23-7 C₁₅H₂₃NO₈ 
• 1194059-42-1 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(hydroxymethyl)-pyrrolidine-2-carboxylic acid methyl ester 
• 1378388-35-2 (3S,5S)-N-(tert-butoxycarbonyl)-5-(methoxycarbonyl)-pyrrolidine-3-carboxylic acid 
• 1378388-19-2 7-(2-bromo-5-chlorobenzyloxy)-3,4-dihydronaphthalene-1(2H)-one 
• 1378388-30-7 (2S,4S)-N-(tert-butyloxycarbonyl)pyrrolidine-2,4-dicarboxylic acid dimethyl ester 
• 487048-28-2 (2S,4S)-4-cyano-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 1378391-39-9 (2S,4S)-1-tert-butyl 2-(2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)ethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 

Downstream Products

• 1378391-44-6 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,4,5,11-tetrahydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1378391-45-7 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1377604-63-1 methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(2S,5S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-5-methylpyrrolidin-2-yl]-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-yl}-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate 
• 1377049-84-7 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 

Relevant articles and documents

Method for preparing NS5A inhibitor-Velpatasvir

The invention discloses a method for preparing an NS5A inhibitor-Velpatasvir, wherein the method mainly comprises the five steps: 1) carrying out docking reaction on reaction initial raw materials VPM1, VPM2 and VPM3 under the catalytic action of alkali to prepare an intermediate VP1; 2) removing amino protecting groups from the intermediate VP1 by using a protecting group removing reagent to prepare an intermediate VP2; 3) carrying out cyclization on the intermediate VP2 and an amine compound to prepare an intermediate VP3; 4) carrying out a reaction on the intermediate VP3 with VPM4 under the action of a condensing agent to prepare an amide compound intermediate VP4; and 5) carrying out oxidation reaction on the intermediate VP4 under the action of an oxidizing agent to prepare Velpatasvir. The preparation process of Velpatasvir has the characteristics of simplified route, simple reaction conditions, enhanced operability and higher product yield, and is more suitable for large-scaleindustrial production.

ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.